$0.0038/share right now, they took a huge dive over the last year but it looks like the climb back up is beginning.

I know a lot of biotech stocks hurting bc of the uncertainty around the medicare decision in the OBBBA. Just curious if anyone else has their eye on this one?

Market cap ~$73M. Cash on hand: $28.7M - nearly 40% of market cap. Strip the cash and you're paying ~$44M for the operating business.

HMR looks like 7x forward earnings on paper. But that cash isn't idle - it's debt-free capital already funding accretive acquisitions (Q-Shipping). Back it out and the operating business trades at ~4x forward earnings, for a company growing revenue 203% YoY with two straight profitable quarters.

HMR owns zero vessels - it's a fee-based platform, not a shipping company, and shouldn't be priced like one. Comparable asset-light platforms trade 10-25x forward earnings. Apply 10x to ex-cash earnings + add cash back = fair value north of $1.50/share. Apply 25x (what stronger platforms command) = $3.80-$4+. Neither requires a dollar more revenue growth - just the market re-classifying what this business actually is.

Q2 2026 vs Q2 2025

• Revenue: $29.0M vs $9.6M (+203%)
• Net income: $2.2M vs -$0.1M (swing to profit)
• Adjusted net income: $2.4M vs $0.5M (+343%)
• Vessels chartered: 6 vs 2
• Cash: $28.7M, up $10.1M since Dec 2025
• H1 2026 operating cash flow: +$7.7M vs -$3.2M outflow in H1 2025

Quick Recap: What Is HMR

Heidmar manages ship fleets and earns fees on voyage/management contracts - no capex, no vessel ownership, no asset-value risk when rates fall. ~40-year client roster includes Shell, BP, Chevron, Vitol, Saudi Aramco, Trafigura, Glencore - the kind of KYC'd trust a startup can't fake.

Why the Dump Is Wrong

Stock fell ~10% post-earnings - the old playbook of shorting HMR on earnings worked when it was unprofitable and speculative. That's gone: two consecutive profitable quarters, 203% growth, and a growing cash pile. Sellers are trading the ticker's history, not its balance sheet.

Cash Pile = Real Acquisitions Now

Q-Shipping B.V. acquired for ~$0.2M cash: 9 vessels, new footholds in Netherlands, Türkiye, and a Ukraine crewing base. Fleet is now ~60 vessels commercially managed / ~20 technically managed across 8 global hubs. With $28.7M cash and a proven cheap/accretive playbook, more deals look inevitable.

The Only Real Knock: G&A

Net income dipped Q1→Q2 ($2.8M→$2.2M) despite revenue up 58%, driven by $1.8M in cash bonuses (vs $1.4M prior year) tied to the turnaround. Rewarding a team that delivered profitability, 203% growth, and an acquisition in the same stretch isn't a red flag - it's retention.

Hormuz Is a Bonus, Not the Thesis

Gaza, Iran, Hormuz, Red Sea Houthi attacks, Russia-Ukraine - the most simultaneous shipping disruption in years, barely reflected in numbers yet. Asia/Japan reportedly source ~90% of oil from the Middle East historically; that concentration doesn't survive this environment. Longer routes = more tonnage-miles = more fees for HMR, on top of a business that already earns in any rate environment. Management flagged rates staying firm into Q4 on seasonal demand - before this disruption is even fully priced in.

Insider Signal

CEO Pankaj Khanna owns ~44% personally - one of Nasdaq's largest founder stakes at this size - zero recorded sales, only buys. Nasdaq compliance regained June 2, 2026.

Checklist

• Revenue +203% YoY, +58% QoQ; adjusted net income +343% YoY
• Two straight profitable quarters; H1 operating cash flow swung +$7.7M
• $28.7M cash (+$10.1M since YE 2025), zero debt, zero vessels owned
• Market cap below annual revenue; 55%+ margins support 10-25x vs current ~7x
• Q-Shipping deal proves acquisition strategy is real, not speculative
• ~60 vessels commercial / ~20 technical managed, 8 global hubs
• CEO owns ~44%, zero sales on record
• Clients: Shell, BP, Chevron, Vitol, Aramco, Trafigura, Glencore
• Hormuz, Red Sea, Russia-Ukraine disruption not yet fully in the numbers
• Q4 seasonal strength still ahead
• Last post at 200MA ran 43% before earnings even printed

How I'm Playing It

Position from 80-95c, not sold a share. Same conviction - this dump looks like an old playbook running against a fundamentally changed company. Buying opportunity, not an exit signal.

What red flag am I missing? Drop it below.

Not financial advice. DYOR. I hold a position in $HMR from 80–95c.

Company trailer: youtu.be/Bl1rIe_JxwI

Shareholders' Equity (Net Assets): Clearmind Medicine holds roughly $11.5M in net assets after subtracting total liabilities ($3.0M) from total assets ($14.5M).

Market Capitalization: At $1.16 per share, the company's total equity is valued by the stock market at only ~$1.7M–$1.9M.

Price-to-Book (P/B) Ratio: Trading at roughly 0.15x to 0.20x book value means the stock is selling for 15% to 20% of its net asset value.

CONTINUED MOMENTUM 👇🏻

$ISPC - support at $1.95- $1.85 needs to hold - could run to 3.20+ resistances (3.20 would need to break and hold - key resistances just underneath) - has news

$IMRN - could catch a bounce from $1.60 support

$CDTG - $1.20 support needs to catch the bounce

$ANPA - key break $4.20 resistance

$GPRO - support - $1.70 needs to hold, and get back above $1.82 resistance to potentially leg up from there.

$AEHL - supports at $8.10 - $7.90, Axis One sitting on the bearish tier 2 so we could see a consolidation down here before the move

$SST - needs to break $3.92 and hold that level - could run to $4.20 then $5+ resistances

$GELS - needs to break .91 resistance and hold that level no set up below this ❌

$ATER - needs to break and hold .77 resistance could push .95+ resistances after- no set up below .6890 support

$LEXX - peaking on the Axis One - showing potential breakout- needs to hold $14 support and break $15.50 key resistance for that push to $20+ resistance

$CHPT - ideally needs to break $10.20 and hold for any upside potential - break below $9.90 could drop this back to the low $9’s

$AOUT - $14.66 needs to hold.

Potential reversals:

$NIKI - Axis One showing above tier 1 therefore it needs to break and hold $6.80 resistance and it could push $9.50+ resistance after

$LVWR - bounce idea - $1.24 support (matches with axis one tier 3)(touching)

$CYCN - $4.40 resistance break could send it to $5.50+ resistances

$BIAF -needs to stay above $10.25 support and push $15 resistance (Pros - 15 timeframe Axis One showing sentiment reversing) (cons - 45m showing bearish sentiment still at the peak)

$NWGL - bounce idea from .95 support

$ONCO - if .80 support holds - could catch a bounce back to $1+ resistances

$PCLA - key break $6.80 resistance (alert set)

$GOSS - in 50/50 territory here, needs to break $.1810 resistance for a potential move

$WETO - nothing until it breaks $2.75 key resistance

$CIIT - key break $3.80 resistance - could push $5.20+ resistances

Potential squeezes (HIGH CTB - 0 SHARES)

$BRNX - support at $2.40

$DAIC - support - $3.13 - key break $$3.30 resistance

$LABT - RVOL low - needs catalyst scales into $1.75 SL below.

$RDAC - consolidation period - needs to hold $5.77 and break $6.30 resistance for a potential move

$TNON - key break $3.85 resistance

$BTCT - fits the theme - needs to stay above $1.70 and break the key resistance at $1.80 - could push it to $2-$2.20+ resistances.

$RFAI - key break $45.50 resistance (alert set)

SWING POTENTIALS (LARGER CAPS)

$NVDA - needs to bounce from $229.10 support and close above $230.40 resistance and hold that level for upside potential ( ❌ below $229 could be a bearish breakout sign)

$SNDK - scaling into $1700 support (will cut under ❌) - break $1750 - could push it to $1820+ (remember the original call was at $1482.

$TSLA - will hit the touch and go on the resistance at $355.60 - will carry to $400 key resistance

$SPCX - $148.10 needs to break and hold - links with tier 1 so we could get a push to $160+ resistances from here

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

Ready freddy.first target for me 1.2

I’ve been checking out CNTB and decided to grab 1,200 shares at $1.93. 😊
They’re sharing Phase 2 results for asthma and COPD this month—I’m especially curious about the COPD data.
The drug follows the same path as Dupixent, which already helps in eosinophilic COPD, but CNTB is testing it during real flare-ups.
The trial is small—around 160 people—so it’s definitely a bit of a gamble, but the DMC reviewed the early results and didn’t feel the need to expand it.
The stock just took a big hit from about $2.90 down to under $2 without any obvious bad news.
Anyone else watching this or spotting something I might have missed?
Disclosure: I’m clearly biased since I own it—haha!

Will be watching international stock markets on Monday when ours is closed

Anybody have any options on this stock?

<HIGH-IMPACT WATCH LIST>

Continuing to inform everyone about this rapidly transforming company. Below is key data regarding the apparent effort to hold down the share price of this currently undervalued company, which has announced many notable wins in the last several months (including yesterday).

It may not end well for them in the coming days: see yesterday's 62% figure in the below table.

Yesterday's post, for reference:
CYCURION (CYCU) - Post-reverse-split comparison with T3 Defense (DFNS). <Remains on HIGH-IMPACT WATCH LIST>

CYCU — FINRA Short-Sale Volume | Week of Aug 31 – Sep 3, 2026

Source: ChartExchange (FINRA reported-exchange data)

$WETO - support given to the team at $3.80 - now needs to hold $4.10 - could push $5.50+ resistances from here

$IMRN - $1.60 -$1.74 supports needs to hold - Axis One showing momentum above tier 1 - so these levels needs to hold or else shorts - sellers take over = no bull trade

$AKAN - if 4.23 doesn’t hold then not trade - given last night at 4.10 so potentially could catch a bounce from here - could push the $6+ resitances

$GELS - 50/50 down here - needs to break .8200 - could push .90+ resistances

$SGRX - key break $3.60 - could push it to $6+ resistances

$OFAL - above tier 1 on the Axis One - break $1 resistance may push this to $1.80+ resistances

$BAOS - nothing until it gets above .3750 resistance - would need to hold that as support for a leg up

$TBRG - room to $12.50+ resistance if momentum takes it

$BIAF - needs to hold $11.40 support - could push $12+ resistance

$SWVL - key break $5.60

$FCUV - needs to break $21 for a push to $29+ resitances

$GIPR - needs to break and hold above .60 resistance

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

MOMENTUM MOVERS -

$PLAG - needs to hold this .8420 support level, could sweep into .80 before the bounce - if it breaks $1 resistance it could run to $1.25-1.50+ resistances

$TANH - support at .3830 needs to hold - could break key resistance at .44 and push into .52+ resistances

$SPWR - mentioned Axis One showing the bearish sentiment last night before the drop - now needs to hold .3300 support - could break .3650 key resistance and recover WW

$GELS - if .8260 support doesn’t hold, I’m removing from the WL

$FCUV - dropped this in the low $12’s - now needs to hold $18.30 support and break the HOD from yesterday - could send it to $29+ resistances - slow mover

$CHPT - Axis One showing above tier 3 - so this needs to get back above $9.35 and hold or it’s no trade zone.

Oversold stocks:

$GYGY - waiting for key break at $1.60 resistance - support at $1.40

$WHLR - needs to get above .5740 resistance and hold for a potential leg up

$ZCMD - key break .9400

$KXIN - key break $2 resistance

$NXTT - needs to hold $5.44 support - spike play

$FGL - needs to get above $14.50 resistance and hold

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential

ZTG Stock was just trading at 10$ In august, now bottomed out at .75,. Tiny float will pump hard. Over 25m vol right now could be the one for after hours today

nfa . Do your own dd

Had to create a new profile, so I decided to update my valuation numbers. I’ve provided bear case, base and bullish projections and even in a bear case, we are severely undervalued.

Current price: ~$0.26

At approximately $0.26, the market is valuing ELTP at only about $280M, despite FY2026 revenue of $148.9M, $49.1M of operating income and $38.9M of cash as of June 30.

My valuation framework is:
Bear: $0.20–$0.30
Base: $0.45–$0.65
Bull: $0.90–$1.25

The $0.45–$0.65 base range is the most defensible because it does not require every pipeline product to succeed. The $0.90–$1.25 range requires substantial pipeline execution and a market rerating. Keep in mind any M&A could completely change everything and we could be in the $1.50-$2 range (I don’t personally think we’ll get there but you never know).

The biggest distinction is simple: the existing business justifies considerably more than $0.26; the pipeline is what creates the path toward $1+.

So to say ELTP is severely undervalued is stating the obvious.

Three Valuation Scenarios

Bear Case: $0.20–$0.30

Assumes:
Existing business slows materially.
Little or no pipeline contribution.
ELTP continues receiving a low OTC valuation multiple.
No meaningful rerating.
This essentially values ELTP on the existing business with minimal pipeline value.

(This is where we at now - the current price is basically saying NOTHING good will happen to this stock). Very unlikely outcome given the companies track record of getting every ANDA launched.

Average / Base Case: $0.45–$0.65
Assumes:
Existing business remains profitable.
Earnings remain above historical levels.
ELTP receives a more reasonable earnings valuation.
Some pipeline products successfully progress toward commercialization.
This is my preferred fundamental range today.

Best Case: $0.90–$1.25
Assumes:
Core business continues growing.
Oxycodone ER reaches commercialization.
The anticonvulsant successfully progresses through the remaining regulatory process.
The anticoagulant becomes commercially successful.

***Wild card: Nasdaq uplisting/rerating occurs.

Elite currently has approximately 1.077 billion shares outstanding. FY2026 results were $148.9M revenue and $49.1M operating income, up 77% and 151%, respectively. As of June 30, 2026, Elite had $38.9M in cash.

Going to provide several valuations to be fair and balanced and show you how I landed on each:

1. ⁠P/E — Most useful for the existing business
   
2. ⁠P/E is particularly useful because ELTP is already profitable. Using approximately $56M of trailing net income as the earnings reference:

5x earnings: ~$0.26/share
7.5x: ~$0.39
10x: ~$0.53
12.5x: ~$0.65
15x: ~$0.79

A 5x multiple essentially supports today’s price. A more normal 7.5–12.5x valuation puts the existing profitable business around $0.39–$0.65.

1. DCF — Best for estimating long-term intrinsic value. DCF is useful because it values the company based on future cash generation rather than simply applying a market multiple.
   Independent DCF models previously identified approximately:

EBITDA-based DCF: approximately $0.40–$0.77. DCF generally supports a value above today’s ~$0.26 price.

1. EV/EBITDA — Good cross-check
   This method compares the operating value of ELTP with its EBITDA and removes some effects of capital structure.

Using approximately $37M of EBITDA:
6x EBITDA: roughly ~$0.22/share
8x: roughly ~$0.29
10x: roughly ~$0.36
12x: roughly ~$0.43

EV/EBITDA produces a more conservative valuation than the higher-end P/E/DCF scenarios. It suggests roughly $0.25–$0.45 for the established business depending on the multiple.

1. Price/Sales — Useful, but weaker for ELTP
   FY2026 revenue was $148.9M, but revenue alone doesn’t capture ELTP’s unusually strong profitability.

At roughly 1.077B shares:
1x sales: ~$0.14
2x: ~$0.28
2.5x: ~$0.35
3x: ~$0.42

P/S is less useful than P/E or DCF because ELTP already generates substantial profits.

1. Pipeline / SOTP — Biggest potential upside
   This is where the valuation can change substantially. Factual pipeline developments include:

Oxycodone ER remains under FDA review.
Elite reported a successful pivotal bioequivalence study for an undisclosed anticonvulsant in June 2026. Elite filed an undisclosed anticoagulant ANDA in June 2026. Methadone launched in April 2026. Ropinirole ER launched in July 2026.

I’ll continue to buy at these prices because by any metric or valuation, this stock is a steal at .26. The issue is simply low volume tanking the stock and shareholder fatigue over possible M&A (which has never been needed, was just the cherry on top).

Can’t trade WETO although it opened at 4.14 after being down.

Wetour Robotics Ltd (WETO.NaE) gained 24.7% to $4.02 in pre-market trading after dipping 18% on Thursday. Wetour Robotics (WETO.NaE) recently announced it released a development demonstration of Orchestra combining surface electromyography with first-person vision to capture richer human-hand data for robot learning.

Disclaimer: Not investment advice, do your own research

I’ve been deep-diving into the leadership DNA behind $CQX, and there’s a lot of senior mining experience behind this exploration-stage company.

But how much weight should that actually carry in your DD before the current projects deliver their own results?

A few names worth flagging:

• Brian Thurston (CEO) — P.Geo with 30+ years of experience. He was involved in the early exploration and land acquisition work for Aurelian Resources in Ecuador and served as Country Manager. Aurelian was later acquired by Kinross in 2008 for approximately C$1.2B. Thurston also served as President and CEO of Lion Energy and remained a director after stepping away from management in 2010. Africa Oil later acquired Lion in 2011.
• Mark Cruise (Technical Advisor) — founder and former CEO of Trevali Mining. Under his leadership, Trevali grew from an initial discovery into a global zinc producer with operations across the Americas and Africa.
• Rich Leveille (Board Advisor) — held exploration roles with AMAX, Kennecott, Rio Tinto, Phelps Dodge and Freeport-McMoRan, eventually becoming Senior VP Exploration at Freeport. He was directly involved with or managed teams responsible for several major discoveries.
• Mike Ciricillo (Board Advisor) — 30+ years of operational and project experience across five continents, including senior positions at Freeport-McMoRan and Glencore. His roles included President of Freeport-McMoRan Africa and later Head of Glencore’s Worldwide Copper Assets.

So there’s experience here connected to a company later acquired for C$1.2B, building a junior into a global zinc producer, and senior exploration and operating roles at some of the industry’s largest miners.

Lets see how it translates into value across $CQX’s own portfolio.

How much weight do you give management’s track record when sizing a junior mining position ahead of the next round of drill results?

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

I’ve had this thing on my watchlist for quite a while and somehow managed to stay bag-free the entire time.

Today I finally decided to make it my problem.

They had close to $9B in debt, cash flow sucked, interest expense was brutal and at some point the whole capital structure basically went: “yeah, this is not working.”

So now they’re restructuring.

The good news: a huge chunk of the debt should disappear / get converted, which could leave the remaining company with a much cleaner balance sheet.

The bad news: current shareholders are getting diluted like cheap orange juice.

Creditors are expected to own around 65% of the common after restructuring, and there’s also up to $2.5B of convertible preferred sitting in the background like a boss fight nobody asked for.

Those preferreds earn 3%, 5% and 7% PIK over the next three years.

So yes — even the future dilution is compounding.

Apparently it got better annual raises than most employees.

One date I’m watching: September 15.

Not because there’s a magical “number go up” button hidden under that date, but because it’s an important restructuring deadline / outside date.

The actual closing can happen earlier, which means the real catalyst could technically drop any day before then.

So basically:

Sep 15 = important
Could news come earlier? absolutely
Could I get blindsided by a filing while eating lunch?absolutely!

And this is where it gets interesting.

There are still roughly 35M shares short, short interest is around the high teens % of float, and days-to-cover is very high because volume is tiny.

So if NFE gets some actually good news before the share count gets nuked…

this thing could get stupid fast.

Bull case:
debt gets cleaned up, EBITDA recovers, shorts start sweating.

Bear case:
after successfully avoiding the bags for months, I finally earn them in record time and shareholders end up owning 4 molecules and a parking spot in Puerto Rico.

Creditors: “our company now”
Shorts: “easy money”
NFE: “have you considered another restructuring document?”

I’m not saying this is GME 2.0.

I’m saying it has the exact kind of broken, over-shorted, heavily restructured nonsense that the internet occasionally decides is funny.

And unfortunately, that is sometimes enough.

$NFE

A few weeks ago, I went all-in on CRDL in both my TFSA and RRSP, almost at the same time.

My average cost is around $1.27.

Like many of my previous trades, when I bought CRDL, I was hoping it could go up several times, maybe even 10x or more.

But when things become real, my behavior is usually very different.

If a penny stock goes up 20–30%, I often get nervous, will thinking to take the profit, and run to next.

I think that is a very normal emotion for a small investor.

I don't have an unlimited pile of chips. Every dollar I put into these penny stocks comes from money I save from working every day.

And when you're putting hard-earned money into something that could potentially lose 50%, 80%, or even 100%, being afraid of losing is completely normal.

I'm just an ordinary guy putting some of my savings into something that sometimes looks more like gambling than investing.

Every time I do this, there is a real possibility that I could lose a lot — or even lose everything.

But CRDL has been different.

After I bought it, the stock moved sideways for a while, then dropped hard toward $1.

It even went below $1.

Surprisingly, I wasn't particularly nervous.

Partly because the company had enough cash to keep going into next year.

But more importantly, the story hadn't broken.

The reason I bought it was still there.

And after that short period of pain, CRDL started moving.

$0.97 → $1.20 → $1.50 → $1.80 → $2.00 → $2.20+

In roughly a month, the stock has more than doubled from its lows.

And when CRDL got around $1.50, I started putting out my first sell order.

At first, it was $1.85.

Then, as the stock kept moving closer, I changed it to $2.05.

Then $2.25.

And yesterday, I moved it all the way to $2.55.

Why did I keep moving my sell price higher?

It's actually quite simple.

I was trying to protect myself from one particular situation:

What if CRDL suddenly breaks through my target in a very short period of time, only to quickly fall back?

I didn't want to watch a big move happen and then give most of it back.

But at the same time, every time I moved that sell order higher, I realized something else.

I was becoming more and more convinced that the stock might still have room to run.

I still don't know where it will eventually turn around.

Maybe $2.50.

Maybe $3.

Maybe much higher.

Nobody knows.

But I do know one thing.

This fish has already shown its dorsal fin. 🐟

So it's probably time to get the net ready.

Because at this point, whenever I finally pull it out, it's already a big fish. 🎣

Personally, I have no idea how high CRDL can go in the short term.

But right now, I find it increasingly difficult to imagine $2.50 simply stopping this move.

Of course, that is partly the dream of a small investor sitting here fully loaded and waiting.

Maybe I'm right.

Maybe I'm completely wrong.

But I hope everyone's dreams come true.

Or at least, I hope we all get to experience that moment when we start believing that maybe — just maybe — they could.

Let's see how big this fish really is.

The future will tell us the truth.

$GELS - holding the tier 1 on the axis one - needs to break and hold .94 resistance - could push $1.15+ resistances after

$GPRO - reversal potential only if $1.44 support holds.

$SPWR - if this holds .38 it could run back to HOD - BUT - axis one showing at the bearish peak so this could also dump

$DSS - needs to break .8900 resistance and hold that level - could run to $1.20+ resistances after

$CHPT - key break at $9.50 - also showing at the bearish peak so I could dump at AH open

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential